Drug Profile


Alternative Names: ZYT-1

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Zydus Cadila
  • Class Antihyperlipidaemics
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyslipidaemias

Most Recent Events

  • 12 Apr 2016 Discontinued - Preclinical for Dyslipidaemias in USA (PO)
  • 12 Apr 2016 Discontinued - Phase-I for Dyslipidaemias in India (PO)
  • 24 Apr 2015 Phase I development for Dyslipidaemias is underway in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top